ACP
COGT icon

Acuta Capital Partners’s Cogent Biosciences COGT Stock Holding History

Acuta Capital Partners’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-102,907
Closed -$1.48M – 32
2025
Q3 		$1.48M Buy
+102,907
New +$1.22M 1.53% 18
2020
Q4 		– Sell
-102,500
Closed -$959K – 53
2020
Q3 		$959K Buy
+102,500
New +$1.07M 0.26% 41

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Acuta Capital Partners's COGT Position: Q4 2025 in Review

Acuta Capital Partners sold out of Cogent Biosciences (COGT) in Q4 2025, closing a stake of 102,907 shares — an estimated $1.48M sold.

Acuta Capital Partners first reported a position in COGT in Q3 2020 and held it in 2 quarters. The position peaked at $1.48M in Q3 2025. 267 funds tracked by Wall St. Rank hold COGT as of Q4 2025.

  • Acuta Capital Partners reported no remaining Cogent Biosciences position as of Q4 2025 after selling out during the quarter.
  • Acuta Capital Partners sold 102,907 Cogent Biosciences shares in Q4 2025, an estimated $1.48M.
  • Acuta Capital Partners first reported a position in Cogent Biosciences in Q3 2020 and held it in 2 quarters.
  • Acuta Capital Partners's Cogent Biosciences position peaked at $1.48M in Q3 2025.
  • 267 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2025.

Based on Acuta Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.